Department of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ 08854, USA.
Toxicology. 2010 Jun 29;273(1-3):35-44. doi: 10.1016/j.tox.2010.04.012. Epub 2010 May 8.
Catalytic activities of CYP1A1, CYP1A2 and CYP1B1, and inducibility of the activities were studied in intact human lung samples (from 23 human subjects) ex vivo. The activities [as measured by ethoxyresorufin O-deethylase (EROD), methoxyresorufin O-demethylase (MROD), and 3-cyano-7-ethoxycoumarin O-deethylase (CECOD)] were present in the lungs and were induced by benzo[a]pyrene (B[a]P) and diesel exhaust particle extract (DEE) but with extensive inter-subject variability. All three activities were substantially inhibited (>or=75%) by the CYP1 inhibitor alpha-naphthoflavone, whereas only MROD and CECOD were substantially inhibited by the CYP1A2-preferential inhibitor fluvoxamine. None of the three activities was substantially inhibited by the CYP1B1-preferential inhibitor tetramethoxystilbene, indicating lack of involvement of CYP1B1 in the activities in the intact lung. CYP1A1 and CYP1A2 proteins were present in the lungs (by western blot analysis), also with extensive inter-subject variability, and were induced by B[a]P or DEE more extensively than by the combination of B[a]P and DEE (B[a]P+DEE). CYP1B1 was also present in the lungs and its level varied extensively between subjects. In contrast with CYP1A and CYP1A2 levels, CYP1B1 level was not significantly altered by B[a]P or DEE treatment and was diminished more extensively by treatment with B[a]P+DEE. The findings point to the potential usefulness of the intact lung for assessing in situ xenobiotic biotransformation reactions as well as the CYP1 specificity of the reactions ex vivo. The findings also suggest MROD and CECOD as potential markers of CYP1A2 activity in the intact lung.
在体外条件下,对 23 位人类供体的完整人肺样本进行了 CYP1A1、CYP1A2 和 CYP1B1 的催化活性及其活性诱导能力的研究。研究发现,这些肺组织中存在着这些酶的活性[通过测定乙氧基-resorufin O-去乙基酶(EROD)、甲氧基-resorufin O-去甲基酶(MROD)和 3-氰基-7-乙氧基香豆素 O-去乙基酶(CECOD)],并且这些酶的活性可被苯并[a]芘(B[a]P)和柴油机排气颗粒提取物(DEE)诱导,但个体间存在较大差异。三种酶的活性均被 CYP1 抑制剂 alpha-萘黄酮(alpha-naphthoflavone)显著抑制(>75%),而 MROD 和 CECOD 的活性则被 CYP1A2 选择性抑制剂氟伏沙明(fluvoxamine)显著抑制。三种酶的活性均未被 CYP1B1 选择性抑制剂四甲氧基二苯乙烯(tetramethoxystilbene)显著抑制,这表明 CYP1B1 并未参与完整肺组织中这些酶的活性。通过 Western blot 分析发现,CYP1A1 和 CYP1A2 蛋白也存在于肺组织中(但个体间存在较大差异),并且它们的活性比 B[a]P 和 DEE 的混合物(B[a]P+DEE)更易被 B[a]P 或 DEE 诱导。CYP1B1 也存在于肺组织中,但其水平在个体间差异较大。与 CYP1A 和 CYP1A2 的水平不同,B[a]P 或 DEE 处理并未显著改变 CYP1B1 的水平,而 B[a]P+DEE 处理则使其水平显著降低。这些发现表明,完整的肺组织在评估原位外源性生物转化反应以及这些反应的 CYP1 特异性方面具有潜在的应用价值。这些发现还提示 MROD 和 CECOD 可能是完整肺组织中 CYP1A2 活性的潜在标志物。